Sequoia Financial Advisors LLC lifted its position in shares of NKGen Biotech, Inc. (NYSE:NKGN – Free Report) by 273.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 69,000 shares of the company’s stock after buying an additional 50,500 shares during the quarter. Sequoia Financial Advisors LLC owned approximately 0.27% of NKGen Biotech worth $26,000 at the end of the most recent quarter.
NKGen Biotech Price Performance
NYSE NKGN opened at $0.29 on Thursday. NKGen Biotech, Inc. has a 1-year low of $0.20 and a 1-year high of $4.06. The business’s 50-day simple moving average is $0.52 and its 200-day simple moving average is $1.00. The firm has a market capitalization of $7.40 million, a P/E ratio of -0.06 and a beta of 0.49.
NKGen Biotech (NYSE:NKGN – Get Free Report) last issued its quarterly earnings results on Thursday, September 12th. The company reported ($0.67) EPS for the quarter.
NKGen Biotech Company Profile
NKGen Biotech, Inc operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials.
Featured Articles
- Five stocks we like better than NKGen Biotech
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- When to Sell a Stock for Profit or Loss
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for NKGen Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NKGen Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
